Gwenaelle Gravis

100

Documents

Affiliation actuelle

Centre de Recherche en Cancérologie de Marseille (CRCM)

Identifiants chercheurs

gwenaelle-gravis
0000-0002-3127-1554
ResearcherID : http://www.researcherid.com/rid/CAG-3019-2022

Présentation

Publications

	Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study Ronan Flippot , Yann-Alexandre Vano , Cécile Dalban , Benoit Beuselinck , Aude Fléchon et al. European Urology, 2026, ⟨10.1016/j.eururo.2025.09.4169⟩ Article dans une revue hal-05423521v1
	Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial Ronac Mamtani , Nobuaki Matsubara , Alvaro Montesa Pino , Urbano Anido Herranz , Gwenaelle Gravis et al. Clinical Genitourinary Cancer, 2025, 23 (1), pp.102248. ⟨10.1016/j.clgc.2024.102248⟩ Article dans une revue hal-05148403v1
	Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial L. Bergmann , L. Albiges , M. Ahrens , M. Gross-Goupil , E. Boleti et al. Annals of Oncology, 2025, 36 (7), pp.796-806. ⟨10.1016/j.annonc.2025.03.016⟩ Article dans une revue hal-05592634v1
	Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand? Arthur Géraud , Paul Gougis , Alexandre de Nonneville , Mathilde Beaufils , François Bertucci et al. Cancer Treatment Reviews, 2025, 135, pp.102922. ⟨10.1016/j.ctrv.2025.102922⟩ Article dans une revue hal-05240065v1
	Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial. Nadine Houédé , Thierry Chevallier , François Audenet , Constance Thibault , Yann Neuzillet et al. Journal of Clinical Oncology, 2025, 43 (13), pp.578-1586. ⟨10.1200/jco-25-00179⟩ Article dans une revue hal-05314103v1
	Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial Adrien Rousseau , Maryam Karimi , Stefan Michiels , Guilhem Roubaud , Xavier Maldonado et al. European Journal of Cancer, 2025, 230, pp.116024. ⟨10.1016/j.ejca.2025.116024⟩ Article dans une revue inserm-05382223v1
	Improving transparency and empowerment for cancer patients by accessing their full online personal medical records Gwenaelle Gravis , Rajae Touzani , Thérèse Aurran , Aude Charbonnier , Domitille Dano et al. Supportive Care in Cancer, 2025, 33, pp.656. ⟨10.1007/s00520-025-09729-7⟩ Article dans une revue hal-05592982v1
	BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells Emilien Billon , Caroline Imbert , Damien Bruyat , Pierre Grassi , Lucie Robert et al. Cell Reports, 2025, 44 (10), pp.116387. ⟨10.1016/j.celrep.2025.116387⟩ Article dans une revue hal-05577986v1
	The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma Geraldine Pignot , Gaelle Margue , Pierre Bigot , Hervé Lang , Loïc Balssa et al. World Journal of Urology, 2025, 43 (1), pp.54. ⟨10.1007/s00345-024-05361-y⟩ Article dans une revue hal-05694855v1
	Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma. Nadine Houede , Thierry Chevallier , Jaffrelot Loic , Constance Thibault , Neuzillet Yann et al. Journal of Clinical Oncology, 2025, 43 (5_suppl), pp.661-661. ⟨10.1200/jco.2025.43.5_suppl.661⟩ Article dans une revue hal-05033783v1
	Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up J. Walz , G. Attard , A. Bjartell , P. Blanchard , E. Castro et al. Annals of Oncology, 2025, pp.S0923-7534(25)06330-6. ⟨10.1016/j.annonc.2025.12.009⟩ Article dans une revue inserm-05435189v1
	PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort Jeremie Naffrichoux , Pierre Poupin , William Pouillot , Claude Linassier , Nathalie Rioux-Leclercq et al. European Journal of Cancer, 2024, 205, pp.114121. ⟨10.1016/j.ejca.2024.114121⟩ Article dans une revue hal-04615732v1
	A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203) A.M. Di Giacomo , M. Schenker , J. Medioni , S. Mandziuk , M. Majem et al. ESMO Open, 2024, 9 (3), pp.102387. ⟨10.1016/j.esmoop.2024.102387⟩ Article dans une revue hal-05141645v1
	Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab Matthew Milowsky , Peter O'Donnell , Christopher Hoimes , Daniel Petrylak , Thomas Flaig et al. Journal of Clinical Oncology, 2024, 42 (12), pp.1403-1414. ⟨10.1200/JCO.23.01547⟩ Article dans une revue hal-05148455v1
	Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study Evan Yu , William Berry , Howard Gurney , Margitta Retz , Henry Conter et al. European Urology Oncology, 2024, 7 (3), pp.509-518. ⟨10.1016/j.euo.2023.10.008⟩ Article dans une revue hal-05148411v1
	PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort. Mathilde Cancel , Jérémie Naffrichoux , Pierre Poupin , William Pouillot , Claude Linassier et al. Journal of Clinical Oncology, 2024, 42 (4_suppl), pp.463. ⟨10.1200/JCO.2024.42.4_suppl.463⟩ Article dans une revue hal-05148453v1
	Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] Matthew Galsky , Dean Bajorin , Johannes Alfred Witjes , Jürgen Gschwend , Yoshihiko Tomita et al. European Urology, 2024, 85 (3), pp.e96-e97. ⟨10.1016/j.eururo.2023.12.013⟩ Article dans une revue hal-05148414v1
	A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1 Neeraj Agarwal , Daniel Castellano , Teresa Alonso-Gordoa , Jose Angel Arranz Arija , Emeline Colomba et al. Clinical Cancer Research, 2024, 30 (11), pp.2377-2383. ⟨10.1158/1078-0432.CCR-23-3436⟩ Article dans une revue hal-05148434v1
	A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study Gwenaelle Gravis , Patricia Marino , Daniel Olive , Frederique Penault-Llorca , Jean-Pierre Delord et al. BMC Cancer, 2023, 23 (1), pp.393. ⟨10.1186/s12885-023-10881-8⟩ Article dans une revue hal-04109560v1
	Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide Lucie-Marie Scailteux , Sebastien Vincendeau , Gwenaelle Gravis , Romain Mathieu , Frederic Balusson et al. Clinical Genitourinary Cancer, 2023, 21 (5), pp.e362-e369. ⟨10.1016/j.clgc.2023.04.004⟩ Article dans une revue hal-04121016v1
	Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial Stéphane Culine , Valentin Harter , Clémentine Krucker , Gwénaëlle Gravis , Aude Fléchon et al. Cancers, 2023, 15 (6), pp.1742. ⟨10.3390/cancers15061742⟩ Article dans une revue hal-04195179v1
	Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma Manon de Vries-Brilland , Nathalie Rioux-Leclercq , Maxime Meylan , Jonathan Dauvé , Christophe Passot et al. Journal for Immunotherapy of Cancer, 2023, Journal for ImmunoTherapy of Cancer, 11 (11), pp.e006885. ⟨10.1136/jitc-2023-006885⟩ Article dans une revue hal-04341909v1
	Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial Valentina Orlando , Damien Drubay , Pernelle Lavaud , Laura Faivre , François Lesaunier et al. Clinical Genitourinary Cancer, 2023, 21 (5), pp.615.e1-615.e8. ⟨10.1016/j.clgc.2023.05.003⟩ Article dans une revue hal-04334564v1
	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN Géraldine Pignot , Rajae Touzani , Marc-Karim Bendiane , Julien Mancini , Jochen Walz et al. Future Oncology, 2022, 18 (14), pp.1733-1744. ⟨10.2217/fon-2021-1420⟩ Article dans une revue inserm-04039329v1
	Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer Anne-Gaëlle Goubet , Leonardo Lordello , Carolina Alves Costa Silva , Isabelle Peguillet , Marianne Gazzano et al. Cancer Discovery, 2022, 12 (10), pp.2280-2307. ⟨10.1158/2159-8290.CD-22-0201⟩ Article dans une revue hal-03951702v1
	Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? Steven Tisseverasinghe , Marwan Tolba , Fred Saad , Gwenaelle Gravis , Boris Bahoric et al. Journal of Clinical Oncology, 2022, 40 (36), pp.4173+. ⟨10.1200/JCO.22.00883⟩ Article dans une revue hal-04084956v1
	Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial Yann-Alexandre Vano , Réza Elaidi , Mostefa Bennamoun , Christine Chevreau , Delphine Borchiellini et al. Lancet Oncology, 2022, 23 (5), pp.612-624. ⟨10.1016/S1470-2045(22)00128-0⟩ Article dans une revue hal-04072026v1
	Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial Émilien Billon , Gwenaelle Gravis , Arnaud Guille , Nadine Carbuccia , José Adélaïde et al. Cancers, 2022, 14 (9), ⟨10.3390/cancers14092275⟩ Article dans une revue hal-04085310v1
	Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study Yann‐alexandre Vano , Letuan Phan , Gwenaelle Gravis , Iphigénie Korakis , Friederike Schlürmann et al. International Journal of Cancer, 2022, 151 (8), pp.1335-1344. ⟨10.1002/ijc.34126⟩ Article dans une revue hal-04085018v1
	The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey Patricia Marino , Rajae Touzani , Jihane Pakradouni , Patrick Ben Soussan , Gwenaelle Gravis Cancers, 2022, 14 (7), pp.1794. ⟨10.3390/cancers14071794⟩ Article dans une revue inserm-04042655v1
	Groupe d'Analyse de Pratique - Expertise Patient (GAP-ExP) : une innovation contributive à la professionnalisation des patients F. Carneiro , A. Vinceneux , M. Larroquette , M. Rony , L. Carril et al. Revue de l'analyse de pratiques professionnelles, 2022, 199 (23), pp.51-74. ⟨10.1016/j.ejca.2024.113534⟩ Article dans une revue hal-05148404v1
	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma Géraldine Pignot , Antoine Thiery-Vuillemin , Laurence Albigès , Jochen Walz , Hervé Lang et al. European Urology Oncology, 2022, 5 (5), pp.577-584. ⟨10.1016/j.euo.2022.07.002⟩ Article dans une revue hal-05699927v1
	Impact of active surveillance for prostate cancer on the risk of depression and anxiety Davidson Sypre , Géraldine Pignot , Rajae Touzani , Patricia Marino , Jochen Walz et al. Scientific Reports, 2022, 12 (1), pp.12889. ⟨10.1038/s41598-022-17224-w⟩ Article dans une revue inserm-04048149v1
	Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review Maelle Rony , Jean-Philippe Ratone , Jochen Walz , Geraldine Pignot , Fabrice Caillol et al. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.644301⟩ Article dans une revue hal-03623317v1
	Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET Gwenaelle Gravis , Aurélie Autret , Morgane Guibert-Broudic , Thomas Dubergé , Christophe Zemmour et al. Clinical Genitourinary Cancer, 2021, 19 (4), pp.346-353. ⟨10.1016/j.clgc.2021.03.004⟩ Article dans une revue hal-03623562v1
	Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial T.K. Choueiri , J. Larkin , S. Pal , R.J. Motzer , B.I. Rini et al. ESMO Open, 2021, 6 (3), pp.100101. ⟨10.1016/j.esmoop.2021.100101⟩ Article dans une revue hal-03623572v1
	Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial Stéphane Culine , Valentin Harter , Gwenaelle Gravis , Aude Fléchon , Christine Chevreau et al. Clinical Genitourinary Cancer, 2021, 19 (6), pp.554-562. ⟨10.1016/j.clgc.2021.08.005⟩ Article dans une revue hal-03625944v1
	Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study Stéphane Culine , Aude Fléchon , Gwenaelle Gravis , Guilhem Roubaud , Yohann Loriot et al. Clinical Genitourinary Cancer, 2021, 19 (4), pp.e216-e222. ⟨10.1016/j.clgc.2021.02.005⟩ Article dans une revue hal-03631553v1
	Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial François Bertucci , Anthony Gonçalves , Arnaud Guille , José Adelaïde , Séverine Garnier et al. Genome Medicine, 2021, 13 (1), pp.87. ⟨10.1186/s13073-021-00897-9⟩ Article dans une revue hal-03583277v1
	Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care Patricia Marino , Rajae Touzani , Lorène Seguin , Jean Francois Moulin , Myriam Palomares et al. Cancers, 2021, 13 (6), pp.1337. ⟨10.3390/cancers13061337⟩ Article dans une revue inserm-03462202v1
	Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors Christine Chevreau , Christophe Massard , Aude Flechon , Rémy Delva , Gwenaëlle Gravis et al. Cancer Medicine, 2021, 10 (7), pp.2250-2258. ⟨10.1002/cam4.3687⟩ Article dans une revue hal-03208728v1
	Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis. Geraldine Pignot , Marion Picini , Patricia Marino , Naji Salem , Stanislas Rybikowski et al. Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.12071-12071. ⟨10.1200/JCO.2021.39.15_suppl.12071⟩ Article dans une revue hal-03623123v1
	Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’ T.K. Choueiri , J. Larkin , S. Pal , R.J. Motzer , B.I. Rini et al. ESMO Open, 2021, 6 (4), pp.100177. ⟨10.1016/j.esmoop.2021.100177⟩ Article dans une revue hal-03623494v1
	665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101 M-O. Grimm , M. Oya , T.K. Choueiri , M. Schmidinger , D.I. Quinn et al. Annals of Oncology, 2021, 32, pp.S690-S691. ⟨10.1016/j.annonc.2021.08.061⟩ Article dans une revue hal-03623392v1
	1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic G. Gravis Mescam , R. Touzani , J. Pakradouni , P. Bens Soussan , P. Marino Annals of Oncology, 2021, 32, pp.S1160. ⟨10.1016/j.annonc.2021.08.1635⟩ Article dans une revue inserm-03667002v1
	Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer Rémi Pelloux-Prayer , Philomène Schiele , Stéphane Oudard , Gwenaëlle Gravis , François Kleinclauss et al. Clinical Genitourinary Cancer, 2021, 19 (5), pp.e326-e333. ⟨10.1016/j.clgc.2021.03.022⟩ Article dans une revue hal-03612906v1
	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales) Mathilde Cancel , Gaelle Fromont , Cyriac Blonz , Christine Chevreau , Nathalie Rioux-Leclercq et al. European Journal of Cancer, 2021, 158, pp.1-11. ⟨10.1016/j.ejca.2021.08.046⟩ Article dans une revue hal-04242387v1
	Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy? Arnaud Méjean , Alain Ravaud , Simon Thezenas , Christine Chevreau , Karim Bensalah et al. European Urology, 2021, 80 (4), pp.417-424. ⟨10.1016/j.eururo.2021.06.009⟩ Article dans une revue hal-03345230v1
	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial Bernadett Szabados , Alejo Rodriguez-Vida , Ignacio Durán , Simon Crabb , Michiel van Der Heijden et al. European Urology Oncology, 2021, 4 (3), pp.456-463. ⟨10.1016/j.euo.2020.11.010⟩ Article dans une revue hal-03623603v1
	Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program Laurence Albiges , Aude Fléchon , Christine Chevreau , Delphine Topart , Gwenaëlle Gravis et al. European Journal of Cancer, 2021, 142, pp.102-111. ⟨10.1016/j.ejca.2020.09.030⟩ Article dans une revue hal-03623382v1
	Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203). Michele Maio , Michael Schenker , Jacques Medioni , Slawomir Mandziuk , Margarita Majem et al. Journal of Clinical Oncology, 2021, 39 (15_suppl), pp.2571-2571. ⟨10.1200/JCO.2021.39.15_suppl.2571⟩ Article dans une revue hal-03623326v1
	Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study Brice Chanez , Fabrice Caillol , Jean-Philippe Ratone , Christian Pesenti , Philippe Rochigneux et al. Cancers, 2021, 13 (21), pp.5267. ⟨10.3390/cancers13215267⟩ Article dans une revue hal-03689914v1
	Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort. Geraldine Pignot , Rajae Touzani , Patricia Marino , Jochen Walz , Stanislas Rybikowski et al. Journal of Clinical Oncology, 2021, 39 (6SUPPL), pp.220-220. ⟨10.1200/JCO.2021.39.6_suppl.220⟩ Article dans une revue inserm-03665171v1
	Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review Maelle Rony , Jean-Philippe Ratone , Jochen Walz , Geraldine Pignot , Fabrice Caillol et al. Frontiers in Oncology, 2021, 11, ⟨10.3389/fonc.2021.710477⟩ Article dans une revue hal-03623373v1
	Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma Emilien Billon , Brice Chanez , Philippe Rochigneux , Laurence Albiges , Cécile Vicier et al. Frontiers in Immunology, 2021, 12, ⟨10.3389/fimmu.2021.670827⟩ Article dans une revue hal-03623028v1
	L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN J Campagna , R Touzani , G Gravis , P Marino , J Walz et al. Progrès en Urologie, 2021, S1166-7087 (21), pp.00213-X. ⟨10.1016/j.purol.2021.08.035⟩ Article dans une revue inserm-03462183v1
	Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey Lorène Seguin , Rajae Touzani , Anne-Déborah Bouhnik , Ali Ben Charif , Patricia Marino et al. Cancers, 2020, 12 (11), pp.3453. ⟨10.3390/cancers12113453⟩ Article dans une revue inserm-03192591v1
	Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses Christian Pfister , Gwenaelle Gravis , Aude Fléchon , Michel Soulié , Laurent Guy et al. European Urology, 2020, ⟨10.1016/j.eururo.2020.08.024⟩ Article dans une revue hal-02995530v1
	Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique C. Pfister , G. Gravis , A. Flechon , M. Soulie , Laurent Guy et al. Progrès en Urologie, 2020, 30 (13), pp.715-716. ⟨10.1016/j.purol.2020.07.038⟩ Article dans une revue hal-02995801v1
	Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial Sylvie Négrier , Nathalie Rioux-Leclercq , Céline Ferlay , Marine Gross-Goupil , Gwénaelle Gravis et al. European Journal of Cancer, 2020, 129, pp.107 - 116. ⟨10.1016/j.ejca.2020.02.001⟩ Article dans une revue hal-02552562v1
	Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors Sotheara Moeung , Christine Chevreau , Sabrina Marsili , Christophe Massart , Aude Fléchon et al. Pharmaceutical Research, 2020, 37 (7), pp.147. ⟨10.1007/s11095-020-02861-5⟩ Article dans une revue hal-02935842v1
	Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring Sotheara Moeung , Christine Chevreau , Vianney Poinsignon , Jérôme Guitton , Bénédicte Lelièvre et al. Therapeutic Drug Monitoring, 2019, 41 (1), pp.66-74. ⟨10.1097/FTD.0000000000000569⟩ Article dans une revue hal-02481351v1
	Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men Rajae Touzani , Julien Mancini , Jaïs Troian , Anne-Déborah Bouhnik , Olivier Cussenot et al. Journal of Patient-Reported Outcomes, 2019, 3 (1), ⟨10.1186/s41687-019-0150-1⟩ Article dans une revue hal-02625852v1
	Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study Ronan Flippot , Cécile Dalban , Brigitte Laguerre , Delphine Borchiellini , Gwénaelle Gravis et al. Journal of Clinical Oncology, 2019, 37 (23), pp.2008--2016. ⟨10.1200/JCO.18.02218⟩ Article dans une revue hal-02931819v1
	Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study Aline Guillot , Charlotte Joly , Philippe Barthélémy , Emeline Meriaux , Sylvie Négrier et al. Clinical Genitourinary Cancer, 2019, 17 (1), pp.e38-e43. ⟨10.1016/j.clgc.2018.08.006⟩ Article dans une revue istex hal-02420071v1
	Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group Marine Sroussi , Reza Elaidi , Aude Fléchon , Marianne Lorcet , Delphine Borchiellini et al. Clinical Genitourinary Cancer, 2019, ⟨10.1016/j.clgc.2019.11.014⟩ Article dans une revue istex hal-02556645v1
	Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5 G. Gravis , R. Touzani , A-D. Bouhnik , P. Marino , G. Pignot et al. Annals of Oncology, 2018, 29 (8) Article dans une revue hal-02143650v1
	The role and use of Patient Reported Outcomes in the management of cancer patients Patricia Marino , Marie Bannier , Jean-François Moulin , Gwenaëlle Gravis Bulletin du Cancer, 2018, 105 (6), pp.603-609. ⟨10.1016/j.bulcan.2018.02.008⟩ Article dans une revue inserm-02096334v1
	Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer Brice Chanez , Max Chaffanet , José Adélaide , Jeanne Thomassin , Séverine Garnier et al. JCO precision oncology, 2018, 2, pp.1-8. ⟨10.1200/po.18.00083⟩ Article dans une revue hal-03623699v1
	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma A. Mejean , A. Ravaud , S. Thezenas , S. Colas , J. -B. Beauval et al. New England Journal of Medicine, 2018, 379 (5), pp.417-427. ⟨10.1056/NEJMoa1803675⟩ Article dans une revue hal-02143533v1
	Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer Claudia S. E. W. Schuurhuizen , Patricia Marino , Annemarie M. J. Braamse , Laurien M. Buffart , Florence Joly et al. Journal of the National Comprehensive Cancer Network, 2018, 16 (12), pp.1481-1488. ⟨10.6004/jnccn.2018.7069⟩ Article dans une revue hal-02143628v1
	Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen Gwenaelle Gravis , Emilien Billon , Capucine Baldini , Christophe Massard , Werner Hilgers et al. European Journal of Cancer, 2018, 104, pp.236-238. ⟨10.1016/j.ejca.2018.09.002⟩ Article dans une revue istex hal-02143638v1
	Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review Philippe Rochigneux , Jeanne Thomassin-Piana , Sophy Laibe , Serge Brunelle , Naji Salem et al. BMC Cancer, 2018, 18 (1), pp.1159. ⟨10.1186/s12885-018-5049-3⟩ Article dans une revue hal-03689938v1
	Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer G. V. Long , S. S. Tykodi , J. G. Schneider , C. Garbe , G. Gravis et al. Annals of Oncology, 2018, 29 (11), pp.2208-2213. ⟨10.1093/annonc/mdy408⟩ Article dans une revue hal-02143540v1
	Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies Gwenaëlle Gravis , Jean-Marie Boher , Yu-Hui Chen , Glenn Liu , Karim Fizazi et al. European Urology, 2018, 73 (6), pp.847-855. ⟨10.1016/j.eururo.2018.02.001⟩ Article dans une revue inserm-02092595v1
	Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study Sotheara Moeung , Christine Chevreau , Sophie Broutin , Jérome Guitton , Bénédicte Lelièvre et al. Clinical Cancer Research, 2017, 23 (23), pp.7171 - 7179. ⟨10.1158/1078-0432.CCR-17-1344⟩ Article dans une revue hal-01659726v1
	Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature Gwenaëlle Gravis , François Audenet , Jacques Irani , Marc-Olivier Timsit , Philippe Barthélémy et al. Cancer Treatment Reviews, 2017, 55, pp.211-217. ⟨10.1016/j.ctrv.2016.09.008⟩ Article dans une revue hal-01632557v1
	Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial P Lavaud , G Gravis , S Foulon , F Joly , S Oudard et al. European Urology, 2017, ⟨10.1016/j.eururo.2017.09.022⟩ Article dans une revue hal-01950269v1
	Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter? Damien Pouessel , Sylvie Chevret , Frédéric Rolland , Gwenaëlle Gravis , Lionel Geoffrois et al. European Journal of Cancer, 2016, 54, pp.69--74. ⟨10.1016/j.ejca.2015.11.017⟩ Article dans une revue istex hal-01278607v1
	Intermediate analysis of a phase II trial assessing gemcitabine and cisplatin in locoregional or metastatic penile squamous cell carcinoma Nadine Houédé , Laura Dupuy , Aude Fléchon , Philippe Beuzeboc , Gwenaëlle Gravis et al. BJU International, 2016, 117 (3), pp.444 - 449. ⟨10.1111/bju.13054⟩ Article dans une revue hal-01938234v1
	Inherent and Tumor-Driven Immune Tolerance in the Prostate Microenvironment Impairs Natural Killer Cell Antitumor Activity Christine Pasero , Gwenaëlle Gravis , Mathilde Guerin , Samuel Granjeaud , Jeanne Thomassin-Piana et al. Cancer Research, 2016, 76 (8), pp.2153-2165. ⟨10.1158/0008-5472.CAN-15-1965⟩ Article dans une revue hal-03599184v1
	Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial Gwenaelle Gravis , Jean-Marie Boher , Florence Joly , Michel Soulié , Laurence Albiges et al. European Urology, 2016, 70, pp.256 - 262. ⟨10.1016/j.eururo.2015.11.005⟩ Article dans une revue inserm-03343628v1
	Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features Romain Mathieu , Géraldine Pignot , Alexandre Ingles , Maxime Crépel , Pierre Bigot et al. Urologic Oncology: Seminars and Original Investigations, 2015, 33 (8), pp.339.e9-339.e15. ⟨10.1016/j.urolonc.2015.05.014⟩ Article dans une revue hal-01260654v1
	Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial Karim Fizazi , Laura Faivre , François Lesaunier , Remy Delva , Gwenaëlle Gravis et al. Lancet Oncology, 2015, 16 (7), pp.787 - 794. ⟨10.1016/S1470-2045(15)00011-X⟩ Article dans une revue istex hal-01914904v1
	Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model Gwenaelle Gravis , Jean-Marie Boher , Karim Fizazi , Florence Joly , Franck Priou et al. European Urology, 2015, 68 (2), pp.196 - 204. ⟨10.1016/j.eururo.2014.09.022⟩ Article dans une revue inserm-03353959v1
	A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma Elodie Jobard , Ellen Blanc , Sylvie Négrier , Bernard Escudier , Gwenaëlle Gravis et al. British Journal of Cancer, 2015, 113 (8), pp.1148-1157. ⟨10.1038/bjc.2015.322⟩ Article dans une revue hal-01234309v1
	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project A. Kramar , S. Negrier , R. Sylvester , S. Joniau , P. Mulders et al. Annals of Oncology, 2015, 26 (12), pp.2392-8. ⟨10.1093/annonc/mdv380⟩ Article dans une revue hal-01913181v1
	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: Long term outcome of the Temporary Authorization for Use program in France. Nadine Houede , Philippe Beuzeboc , Sophie Gourgou , Diego Tosi , Laura Moise et al. Journal of Clinical Oncology, 2015, 33 (7_suppl), pp.264-264. ⟨10.1200/jco.2015.33.7_suppl.264⟩ Article dans une revue hal-03578471v1
	Abiraterone acetate in patients with metastatic castration-resistant prostate cancer: long term outcome of the Temporary Authorization for Use programme in France Nadine Houédé , Philippe Beuzeboc , Sophie Gourgou , Diego Tosi , Laura Moise et al. BMC Cancer, 2015, 15 (1), pp.222. ⟨10.1186/s12885-015-1257-2⟩ Article dans une revue inserm-01264474v1
	Combining gemcitabine, cisplatin, and ifosfamide (GIP) is active in patients with relapsed metastatic germ-cell tumors (GCT): a prospective multicenter GETUG phase II trial K. Fizazi , G. Gravis , Aude Flechon , L. Geoffrois , C. Chevreau et al. Annals of Oncology, 2014, 25, pp.987--91. ⟨10.1093/annonc/mdu099⟩ Article dans une revue hal-02168058v1
	Patients’ self-assessment versus investigators’ evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15). Gwenaëlle Gravis , Patricia Marino , Florence Joly , Stéphane Oudard , Franck Priou et al. European Journal of Cancer, 2014, pp.953 - 962. ⟨10.1016/j.ejca.2013.11.034⟩ Article dans une revue istex hal-01917876v1
	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis Benoit Beuselinck , Alexandra Karadimou , Diether Lambrechts , Bart Claes , Pascal Wolter et al. Acta Oncologica, 2014, 53 (1), pp.103--112. ⟨10.3109/0284186X.2013.770600⟩ Article dans une revue hal-01064635v1
	FGFR1 and WT1 are markers of human prostate cancer progression. Elizabeth Devilard , Franck Bladou , Olivier Ramuz , Gilles Karsenty , Jean-Philippe Dalès et al. BMC Cancer, 2006, 6, pp.272. ⟨10.1186/1471-2407-6-272⟩ Article dans une revue inserm-00121110v1
	Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens D. Genre , P. Viens , F. Bertucci , C Chabannon , G. Gravis et al. Bone Marrow Transplantation, 2002, 29 (11), pp.881-886. ⟨10.1038/sj.bmt.1703556⟩ Article dans une revue inserm-03199676v1
	Quality of life of breast cancer patients receiving high-dose-intensity chemotherapy: impact of length of cycles Dominique Genre , C. Protière , Geneviève Macquart-Moulin , G. Gravis , Jacques Camerlo et al. Supportive Care in Cancer, 2002, 10 (3), pp.222-230. ⟨10.1007/s00520-001-0322-3⟩ Article dans une revue istex inserm-03199677v1
	Benefits of granulocyte-colony-stimulating factor after stem cell transfusion in intensive sequential chemotherapy for breast cancer Patrice Viens , Dominique Genre , Christel Protiere , Gwenaelle Gravis , François Bertucci et al. European Cytokine Network, 1998, 9 (1), pp.93-98 Article dans une revue inserm-04975072v1

	A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer. Gwenaelle Gravis , Patrick Sfumato , Guillaume Ploussard , Pierre Henri Savoie , Matthieu Durand et al. ASCO Genitourinary Cancers Symposium, Feb 2026, San Francisco, United States. pp.363, ⟨10.1200/JCO.2026.44.7_suppl.363⟩ Communication dans un congrès hal-05625153v1
	Management of patients with advanced prostate cancer—metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022 S. Gillessen , Alberto Bossi , Ian D. Davis , Johann Sebastian de Bono , Karim S. Fizazi et al. unknow, 2023, unknow, France. pp.178-215, ⟨10.1016/j.ejca.2023.02.018⟩ Communication dans un congrès hal-04107713v1
	Analyse en vie réelle des séquences de traitement de patients initiant de l&#039;abiratérone et de l&#039;enzalutamide pour un cancer de prostate résistant à la castration métastatique L. M. Scailteux , S. Vincendeau , G. Gravis , F. Balusson , R Mathieu et al. Congrès EMOIS 2023, Mar 2023, Nancy, France. pp.101430-101430, ⟨10.1016/j.respe.2023.101430⟩ Communication dans un congrès hal-04284910v1
	A non-inferiority randomized phase III trial of standard immunotherapy versusreduced dose intensity in responding patients with metastatic cancer: MOIO study. Gwenaelle Gravis , Daniel Olive , Patricia Marino , Frederique Madeleine Penault-Llorca , Jean-Pierre Delord et al. ASCO, 2022, Chicago, United States. pp.TPS2674, ⟨10.1200/JCO.2022.40.16_suppl.TPS2674⟩ Communication dans un congrès hal-03929783v1

Chargement...

Gwenaelle Gravis

Présentation

Publications

Publications

Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study

Outcomes by Retrospective Eligibility for Maintenance Therapy of Patients With Advanced Urothelial Carcinoma: Post Hoc Analysis of the Phase 3 KEYNOTE-361 Trial

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?

Safety and efficacy of neoadjuvant durvalumab plus gemcitabine/cisplatin or carboplatin in patients with operable high-risk upper tract urothelial carcinoma: the iNDUCT trial.

Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial

Improving transparency and empowerment for cancer patients by accessing their full online personal medical records

BTN2A1 acquisition through trogocytosis enhances Vγ9Vδ2 T cell cytotoxicity against autologous and cancer cells

The effect of tumor downsizing on surgical complexity during nephrectomy after immune checkpoint inhibitors for metastatic renal cell carcinoma

Safety and efficacy of neoadjuvant immunotherapy with durvalumab (MEDI 4736) in combination with neoadjuvant chemotherapy (gemcitabine/cisplatin or carboplatin) in patients with operable high-risk upper tract urothelial carcinoma.

Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203)

Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab

Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate–Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study

PD-L1 expression and its prognostic value in metastatic papillary renal cell carcinoma: Results from a GETUG multicenter retrospective cohort.

Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440]

A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1

A non-inferiority randomized phase III trial of standard immunotherapy by checkpoint inhibitors vs. reduced dose intensity in responding patients with metastatic cancer: the MOIO protocol study

Real-World Treatment Patterns Among French Patients With Metastatic Castration-Resistant Prostate Cancer Under Abiraterone or Enzalutamide

Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Comprehensive analyses of immune tumor microenvironment in papillary renal cell carcinoma

Very Long‐Term Complete Remission Can Be Achieved in Men With High‐Risk Localized Prostate Cancer and a Very High PSA Value: An Analysis of the GETUG 12 Phase 3 Trial

Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN

Escherichia coli –Specific CXCL13-Producing TFH Are Associated with Clinical Efficacy of Neoadjuvant PD-1 Blockade against Muscle-Invasive Bladder Cancer

Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

Cabozantinib-nivolumab sequence in metastatic renal cell carcinoma: The CABIR study

The Psychological Distress of Cancer Patients following the COVID-19 Pandemic First Lockdown: Results from a Large French Survey

Groupe d'Analyse de Pratique - Expertise Patient (GAP-ExP) : une innovation contributive à la professionnalisation des patients

Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma

Impact of active surveillance for prostate cancer on the risk of depression and anxiety

Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review

Prognostic Risk Classification for Biochemical Relapse-Free Survival in Oligometastatic Recurrent Prostate Cancer Determined by Choline PET

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

Advance Approval of Outpatient Chemotherapy via Phone Call Optimizes Healthcare Delivery without Compromising Patient Satisfaction with Care

Multicentric phase II trial of TI‐CE high‐dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors

Feasibility and first results of digital patient-reported outcomes measures (PROMs) data collection for patients with localized prostate cancer at diagnosis.

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’

665P Role of prior nephrectomy for synchronous metastatic renal cell carcinoma (mRCC) on efficacy in patients treated with avelumab + axitinib (A + Ax) or sunitinib (S): Results from JAVELIN Renal 101

1642P Improve the conditions of lockdown may decrease anxiety among cancer patients during the COVID-19 pandemic

Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic Prostate Cancer

Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Genitales)

Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?

Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial

Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).

Endoscopic Ultrasound-Guided Radiofrequency Ablation as an Future Alternative to Pancreatectomy for Pancreatic Metastases from Renal Cell Carcinoma: A Prospective Study

Impact of active surveillance for prostate cancer on the risk of depression and anxiety: Patient-reported outcomes (PROs) from the Vican Prospective Cohort.

Corrigendum: Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma

L’annonce du cancer au diagnostic de Tumeur de vessie non infiltrant le muscle modifie-t-elle la qualité de vie et l’observance des patients ? Données de la cohorte prospective française VICAN

Deterioration of Sexual Health in Cancer Survivors Five Years after Diagnosis: Data from the French National Prospective VICAN Survey

Essai GETUG/AFU-V05 VESPER phase III randomisée de chimiothérapie périopératoire (schéma MVAC dose-dense ou GC) dans le cancer de vessie infiltrant localisé. Résultats sur la toxicité de la chimiothérapie et la réponse histologique

Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trial

Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors

Estimation of Unbound Carboplatin Clearance From Total Plasma Concentrations as a Means of Facilitating Therapeutic Drug Monitoring

Adaptation and validation of the memorial anxiety scale for prostate cancer (MAX-PC) in a sample of French men

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Denosumab Toxicity When Combined With Anti-angiogenic Therapies on Patients With Metastatic Renal Cell Carcinoma: A GETUG Study

Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group

Gender difference in cancer survivors' perceived information 5-years after diagnosis: Data from the French national study - VICAN 5

The role and use of Patient Reported Outcomes in the management of cancer patients

Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma

Impact of Patient- and Clinician-Reported Cumulative Toxicity on Quality of Life in Patients With Metastatic Castration-Naive Prostate Cancer

Unexpected response to cisplatin rechallenge after immune checkpoint inhibitors in patients with metastatic urothelial carcinoma refractory to platinum regimen

Long-term efficacy of crizotinib in a metastatic papillary renal carcinoma with MET amplification: a case report and literature review

Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer

Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies

Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study

Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature

Analyse en vie réelle des séquences de traitement de patients initiant de l'abiratérone et de l'enzalutamide pour un cancer de prostate résistant à la castration métastatique